Senti Biosciences (SNTI) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
3 Mar, 2026Key technology and therapeutic approach
Logic-gated cell therapies selectively kill cancer cells while sparing healthy cells, addressing a major challenge in oncology treatment.
SENTI-202 is an off-the-shelf allogeneic NK cell therapy targeting CD33 and FLT3, covering over 95% of AML patients.
The therapy uses an activating CAR for cancer targets, an inhibitory CAR for healthy cells, and IL-15 to enhance NK activity.
Logic-gating technology is adaptable to both NK and T cells and is being explored for solid tumors.
SENTI-202 is not genetically restricted, allowing broad patient eligibility.
Clinical data and outcomes
In a phase I study with relapsed/refractory AML patients, SENTI-202 achieved a 50% overall response rate and 42% CR/CRh at RP2D, with a 7.6-month median duration of CRs.
100% of CRs were MRD negative, indicating deep responses and potential for improved patient outcomes.
The safety profile was favorable, with most adverse events related to lymphodepletion and manageable; no significant CRS observed.
Responses were observed across patients with adverse genetic features and those refractory to prior therapies.
Outpatient dosing is feasible, and the product is suitable for rapid delivery due to its off-the-shelf nature.
Mechanism of action and differentiation
SENTI-202's logic gate design enables selective killing of AML blasts and leukemic stem cells while sparing healthy hematopoietic stem cells.
CyTOF analysis confirmed maintenance or increase of healthy stem cells in responders, supporting the logic gate's function.
The therapy is effective even in patients with high-risk genetics, including complex karyotypes.
The approach is differentiated from existing therapies by not requiring specific genetic mutations and by targeting both AML blasts and stem cells.
The technology is being adapted for solid tumors, with proof-of-concept shown for CEA-positive cancers using a NOT gate to protect healthy cells.
Latest events from Senti Biosciences
- SENTI-202 achieved 42% CR/CRh in AML with strong safety and rapid recovery, advancing to pivotal trials.SNTI
Leerink Global Healthcare Conference 20269 Mar 2026 - SENTI-202 and SENTI-301A advance clinical cell therapies with Logic Gate technology for cancer.SNTI
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Multi-target cell therapies advance in AML and liver cancer, with key data readouts ahead.SNTI
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026 - SENTI-202 demonstrates durable, selective efficacy in AML, with expansion into solid tumors planned.SNTI
H.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025 - Biotech seeks $300M via shelf, faces going concern risk and dilution; Leerink Partners leads ATM.SNTI
Registration Filing16 Dec 2025 - Highly dilutive PIPE resale registration funds R&D amid financial uncertainty and investor-led governance.SNTI
Registration Filing16 Dec 2025 - 50% ORR and 42% CR/CRh with deep, durable, MRD-negative remissions and high safety.SNTI
Study Update9 Dec 2025 - Stockholders to vote on major stock issuance, equity plan expansion, and meeting adjournment.SNTI
Proxy Filing2 Dec 2025 - Virtual annual meeting to elect directors, ratify auditor, and address governance and compensation.SNTI
Proxy Filing2 Dec 2025